eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

In the AUGUSTUS clinical trial, ELIQUIS demonstrated superiority over VKA for major or CRNM bleeding in patients with NVAF after a recent ACS and / or PCI1,2*

  • There is limited experience of treatment with
    ELIQUIS at the recommended dose for NVAF
    patients when used in combination with
    antiplatelet agents in patients with ACS and /
    or undergoing PCI after haemostasis is
    achieved.2

Discover the data on the safety outcome
of ELIQUIS in patients with NVAF after a
recent ACS and / or PCI

Watch the video below to learn how the
AUGUSTUS trial may support your
treatment decisions in patients with NVAF
after a recent ACS and / or PCI1

Purple information icon ELIQUIS® (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS® (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

* The AUGUSTUS clinical trial was a two-by-two factorial, randomised, controlled clinical trial in 4,614 patients who had an ACS or had undergone PCI. Patients were randomly assigned to receive open-label ELIQUIS 5 mg BD (or 2.5 mg BD in selected patients [4.2%]) or a VKA and to receive double-blind aspirin (81 mg) or matching placebo OD.2 The primary outcome for both factorial comparisons was major or CRNM bleeding as defined by the ISTH. Secondary outcomes included the composite of death or hospitalisation and the composite of death or ischaemic events (stroke, myocardial infarction, definite or probable stent thrombosis, or urgent revascularisation).1

† ISTH defined major bleeding as bleeding that resulted in death, occurred in a critical organ (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, intramuscular with compartment syndrome, or pericardial), or was associated with either a decrease in the haemoglobin level of at least 2 g/dl or a transfusion of at least 2 units of packed red cells.1

‡ CRNM was defined as bleeding that resulted in hospitalisation, medical or surgical intervention for bleeding, an unscheduled clinic visit, or a change in physician-directed antithrombotic therapy.1

§ Aspirin was administered at a dose of 81 mg QD.1

ACS = Acute Coronary Syndrome   
AF = Atrial Fibrillation    ARR = Absolute Risk Reduction   
BD = Twice Daily   
CI = Confidence Interval   
CRNM = Clinically Relevant Non-Major   
HR = Hazard Ratio   
INR = International Normalised Ratio   
ISTH = International Society on Thrombosis and Haemostasis   
NNH = Number Needed to Harm   NNT = Number Needed to Treat   NS = Not Significant   
NSAID = Non-Steroidal Anti-Inflammatory Drug   
NVAF = Non-Valvular Atrial Fibrillation   
OAC = Oral Anticoagulant    OD = Once Daily   
PCI = Percutaneous Coronary Intervention    
P2Y12 = Purinergic signalling receptor Y12   
SmPC = Summary of Product Characteristics   
TTR = Time in Therapeutic Range    
VKA = Vitamin K Antagonist

References

  1. Lopes RD et al. N Engl J Med 2019; 380: 1509–1524.
  2. ELIQUIS® (apixaban) Summary of Product Characteristics.